Clinical Trial Update: Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies [Phase 2]

View source ↗

Summary

Phase II trial evaluating Ubamatamab alone or with Cemiplimab for MUC16-expressing SMARCB1-deficient malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smarcb1-deficient Malignancies

Drugs mentioned

• Cemiplimab (cemiplimab)
• Ubamatamab (ubamatamab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: SMARCB1-Deficient Malignancies | Phase 2 | Status: RECRUITING